Phase 3
Completed N=81
Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents
Contraceptive Usage
Source: ClinicalTrials.gov NCT03585504 ↗
Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum — 15; 7 Participants
◆ Published Evidence
Established
31citations · ~8 / year
Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception.
Summary
The specific aim of this study is to evaluate whether insertion of a long-acting contraceptive implant in postpartum adolescents prior to hospital discharge increases use of this highly effective contraception during the first twelve months postpartum among adolescents who elect Implanon® as their preferred method of contraception. Additionally, this study aims to compare the acceptability of bleeding in postpartum adolescents who have an etonogestrel contraceptive implant prior to discharge versus those with insertion at the six week postpartum visit. The investigators will evaluate the acceptability of bleeding rather than collect prospective diaries because the investigators feel subjective perceptions of bleeding impact contraceptive continuation more than quantitative differences in bleeding.
Linked Publications
-
Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum |
15; 7 | — |
| SECONDARY Number of Participants That Reported They Were Somewhat or Very Satisfied With Their Subjective Bleeding Experience at Six Months Postpartum. |
10; 8 | — |
| SECONDARY Number of Participants Who Reported That They Were Somewhat or Very Satisfied With the Contraceptive Implant at Six Months Postpartum. |
14; 6 | — |
Eligibility Criteria
Inclusion Criteria
- ages 15-21
- women
- english or spanish speaking
- less than 120 hours post partum
Exclusion Criteria
- women who are breastfeeding
- contraindications to Implanon® insertion including current or prior thrombo-embolic disease, liver disease, hypersensitivity to components of Implanon®, or are using medications such as rifampin, phenytoin, or carbamazepine that increase metabolism of steroid hormones.
- indicate unwillingness to continue follow-up for one year.
Data sourced from ClinicalTrials.gov (NCT03585504) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.